Literature DB >> 27515804

Effects of chronic administration of the phosphodiesterase inhibitor vardenafil on serum levels of adrenal and testicular steroids in men with type 2 diabetes mellitus.

Daniele Santi1,2, Antonio Rm Granata3, Elisa Pignatti4,5, Tommaso Trenti6, Laura Roli6, Roberto Bozic7, Stefano Zaza8, Chiara Pacchioni9, Vincenzo Rochira4,3, Cesare Carani4, Manuela Simoni4,3,5.   

Abstract

To investigate whether long-term, chronic treatment with the phosphodiesterase-5 inhibitor vardenafil affects adrenal and testicular steroidogenesis in diabetic men, using liquid chromatography-tandem mass spectrometry. A longitudinal, prospective, investigator-started, randomized, placebo-controlled, double-blind, clinical-trial was carried out, enrolling 54 male patients affected by type 2 diabetes mellitus diagnosed within the last 5 years. In total, 26 and 28 patients were followed for 1 year and assigned to the study and placebo group, respectively. Progesterone, 17-hydroxyprogesterone, androstenedione, testosterone, dehydroepiandrosterone, dehydroepiandrosterone sulfate, corticosterone, 11-deoxycortisol and cortisol, were evaluated using liquid chromatography-tandem mass spectrometry. No differences were seen in sex testicular steroids between study and control group. As for the adrenal gland, steroids were considered according to the zona in which they are produced. No significant differences were seen in steroid produced in zona fasciculata. For the zona reticularis, dehydroepiandrosterone significantly decreased during treatment only in the study group (p = 0.007), with higher levels at visit 2 and 8 than other visits. The dehydroepiandrosterone sulfate/dehydroepiandrosterone ratio significantly increased during treatment only in the verum group. Considering the adrenal zona glomerulosa, corticosterone significantly changed among visits both in both groups (p < 0.001), with higher levels at visit 2 (p = 0.028), 8 (p = 0.003), and 10 (p = 0.044), i.e., in coincidence with the complete clinical and instrumental examination performed only at these visits according to the study protocol. Chronically administered vardenafil reduces dehydroepiandrosterone levels and increases dehydroepiandrosterone sulfate/dehydroepiandrosterone ratio as possible consequences of modulation of steroidogenic enzymes by tissue changes in cyclic adenosine monophosphate and cyclic guanosine monophosphate availability. A possibly stress-related increase in corticosterone is suggested for the first time.

Entities:  

Keywords:  Adrenal steroid; Mass-spectrometry; Type 2 diabetes mellitus; Vardenafil

Mesh:

Substances:

Year:  2016        PMID: 27515804     DOI: 10.1007/s12020-016-1055-x

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  53 in total

Review 1.  Molecular biology of steroid hormone synthesis.

Authors:  W L Miller
Journal:  Endocr Rev       Date:  1988-08       Impact factor: 19.871

Review 2.  PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer.

Authors:  Anindita Das; David Durrant; Fadi N Salloum; Lei Xi; Rakesh C Kukreja
Journal:  Pharmacol Ther       Date:  2014-10-31       Impact factor: 12.310

3.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.

Authors:  K G Alberti; P Z Zimmet
Journal:  Diabet Med       Date:  1998-07       Impact factor: 4.359

4.  Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.

Authors:  Annamaria Morelli; Sandra Filippi; Rosa Mancina; Michaela Luconi; Linda Vignozzi; Mirca Marini; Claudio Orlando; Gabriella Barbara Vannelli; Antonio Aversa; Alessandro Natali; Gianni Forti; Mauro Giorgi; Emmanuele A Jannini; Fabrizio Ledda; Mario Maggi
Journal:  Endocrinology       Date:  2004-02-05       Impact factor: 4.736

Review 5.  Mechanisms of action of PDE5 inhibition in erectile dysfunction.

Authors:  J D Corbin
Journal:  Int J Impot Res       Date:  2004-06       Impact factor: 2.896

6.  Chronic treatment with sildenafil stimulates Leydig cell and testosterone secretion.

Authors:  Karina Lidianne Alcântara Saraiva; Amanda Karolina Soares E Silva; Maria Inês Wanderley; Araken Almeida De Araújo; José Roberto Botelho De Souza; Christina Alves Peixoto
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

7.  Six months of daily treatment with vardenafil improves parameters of endothelial inflammation and of hypogonadism in male patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, prospective trial.

Authors:  Daniele Santi; Antonio R M Granata; Alessandro Guidi; Elisa Pignatti; Tommaso Trenti; Laura Roli; Roberto Bozic; Stefano Zaza; Chiara Pacchioni; Stefania Romano; Jerzy Roch Nofer; Vincenzo Rochira; Cesare Carani; Manuela Simoni
Journal:  Eur J Endocrinol       Date:  2016-01-20       Impact factor: 6.664

Review 8.  Insulin resistance and endothelial cell dysfunction: studies in mammalian models.

Authors:  Mark T Kearney; Edward R Duncan; Mathew Kahn; Stephen B Wheatcroft
Journal:  Exp Physiol       Date:  2007-10-12       Impact factor: 2.969

9.  Protein kinase G-mediated stimulation of basal Leydig cell steroidogenesis.

Authors:  Silvana A Andric; Marija M Janjic; Natasa J Stojkov; Tatjana S Kostic
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-09-11       Impact factor: 4.310

10.  A yeast-based chemical screen identifies a PDE inhibitor that elevates steroidogenesis in mouse Leydig cells via PDE8 and PDE4 inhibition.

Authors:  Didem Demirbas; Arlene R Wyman; Masami Shimizu-Albergine; Ozgur Cakici; Joseph A Beavo; Charles S Hoffman
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more
  1 in total

Review 1.  The "Hitchhiker's Guide to the Galaxy" of Endothelial Dysfunction Markers in Human Fertility.

Authors:  Daniele Santi; Giorgia Spaggiari; Carla Greco; Clara Lazzaretti; Elia Paradiso; Livio Casarini; Francesco Potì; Giulia Brigante; Manuela Simoni
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.